MedTrace Logo

Reporting, Evaluating, Preventing and Treating the Cardiotoxicity Induced by Anticancer Drugs During a Specific Cardio-oncology Consult and Follow up in Routine Care

NCT03882580 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 5000

Last updated 2023-04-24

No results posted yet for this study

Summary

Several Drugs used in routine care in oncology induce rare but often severe or fatal cardiovascular or metabolic side effects. This study will investigate, evaluate, report and treat the cardiovascular side effects of anticancer drugs, through a specific cardiovascular routine checkup and follow-up taking place in several Cardio-oncology programs throughout France. The different including centers will be: Assistance Publique - Hôpitaux de Paris (APHP.6: Pitié-Salpétrière, Saint Antoine and Tenon's hospitals, Paris, France).

Conditions

  • Cardiovascular Complication
  • Cardiovascular Insufficiency
  • Cardiac Complication
  • Oncologic Complications
  • Cardiac Insufficiency
  • Metabolic Disorder
  • Vascular Disorder
  • Cardiac Disorder

Interventions

DRUG

Anti-Cancer Agents

Drugs and treatments used in cancer inducing cardiovascular and metabolic side effects

Sponsors & Collaborators

  • Groupe Hospitalier Pitie-Salpetriere

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-03-01
Primary Completion
2025-03-01
Completion
2025-03-01
FDA Drug
Yes

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03882580 on ClinicalTrials.gov